KANSAS CITY, Kan. and BOSTON, Jan. 31, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has closed on a $12 million Series C financing. Proceeds will fund the continued expansion of Aratana’s pipeline of companion animal therapeutic products. Existing Aratana investors, as well as new investors, participated in the over-subscribed financing.
“Aratana is on a strong growth trajectory,” stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. “As we focus on advancing our current development pipeline toward approval and commercialization, we will use funds from this round to add to our portfolio of animal health products, ensuring Aratana’s future growth. We thank our investors for their support and enthusiasm and together we look forward to continued successful execution from our expert senior development and commercial team.”
About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals). Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market. For more information, please visit www.aratanatherapeutics.com.
For Investors & Media:
Joshua Drumm, Ph.D. / Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
amielach@tiberend.com
SOURCE Aratana Therapeutics
